stockrow
Saturday 7 November 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024.
15.78
0.93
+6.26%
Follow AKTS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | 6 | 10 | +336.9% | 11 | 10 | 10 | +13.6% | |
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | (29) | (44) | (64) | (76) | +49.2% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | (2,957.63) | (980.93) | (781.95) | (980.9) pt | ||||||
| Net income | — | — | — | — | — | — | — | (29) | (44) | (64) | (124) | +49.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 2.11 | 7.99 | 0.17 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (46.55) | (62.46) | (78.34) | (41.81) | +29.7% | ||||||
| Cash flow | — | — | — | — | — | — | — | (48.77) | 20.96 | (78.83) | (2.26) | +27.1% | ||||||
| Capex | — | — | — | — | — | — | — | (6.03) | (4.06) | (11.78) | (0.26) | +39.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (54.80) | 16.90 | (90.61) | (2.52) | +28.6% | ||||||
| Book value | — | — | — | — | — | — | — | 168.63 | (124.68) | 230.19 | 8.77 | +16.8% | ||||||
| Shares, m | — | — | — | — | — | — | — | 1 | 1 | 1 | 26 | +15.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 90.34 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.80 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 36.79 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 2.11 | 2.11 | (2.55) | 2.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (30) | 15 | (64) | (125) | +46.2% | |||||
| Capex | — | — | — | — | — | — | — | (4) | (3) | (10) | (14) | +60.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (34) | 12 | (74) | (139) | +47.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 94 | 282 | 199 | 492 | +45.6% | |||||
| Net debt | — | — | — | — | — | — | — | (98) | (297) | (227) | (517) | +52.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 104 | (88) | 187 | 485 | +34.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (19.61) | (21.56) | (22.22) | (21.6) pt | |||||
| ROIC | — | — | — | — | — | — | — | (369.71) | 0.00 | 0.00 | 0.00 | +369.7 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 65.59 | 54.48 | (34.45) | +54.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 76 | 79 | — | +3.9% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.02 | 0.08 | — | +320.3% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Aktis Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IVA Inventiva S.A. Sponsored ADR | $867.9M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LTGO Latigo Biotherapeutics Inc | $862.6M | — | — | — | n/m | — | — | 0.00% | Compare |
| ANRO Alto Neuroscience, Inc. | $858.2M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $853.9M | 2.4× | 16.4× | +16.45% (above 0%: growing) | −54.84% (below 0%: shrinking) | +43.90% (above 0%: growing) | 86.67% | 21.15% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $843.6M | — (loss-making) | — (loss-making) | +81.59% (above 0%: growing) | n/m | +61.43% (above 0%: growing) | 83.20% | (50.30%) | Compare |
| AKTS Aktis Oncology, Inc. | $826.0M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | |
| CRVS Corvus Pharmaceuticals, Inc. | $818.5M | — (loss-making) | — | — | n/m | −171.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MGTX MeiraGTx Holdings PLC | $817.3M | 11.8× | 30.3× | +8,608.59% (above 0%: growing) | n/m | +13.06% (above 0%: growing) | 97.77% | 76.04% | Compare |
| PRME Prime Medicine, Inc. | $807.1M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | Compare |
| Median of peers | $848.7M | — | — | +16.45% | — | +4.40% | 84.94% | 0.00% |